MagnaPharm consortium delivers 'excellent' results in Brussels

7th March 2019

The MagnaPharm consortium gathered this week for the first Scientific Action Check meeting (deliverable D4.9), held at the European Commission Research Executive Agency (REA) in Brussels.

 

The key objectives of the meeting were to assess:​

- the degree to which the work plan has been carried out and all due deliverables have been completed

- the continued relevance of our objectives and their potential for scientific or industrial breakthrough

- how well resources have been planned and used in relation to the achieved progress

- the management procedures and methods of the action

- the expected potential scientific, technological, economic, competitive and social impact and plans for using and disseminating our results

The day kicked off with a welcome and opening by Adriana Godeanu Metz, EC Project Officer for MagnaPharm. ​

The table was then opened to the Work Package leaders and PDRAs to present our scientific and technological progress to date with respect to the DoA. These presentations can be found here. 

Nicole Dixon (Project Officer) then delivered an overview of the project, introducing the new strategy for dissemination & exploitation, Open Access, management and communication.

 

This was followed by a discussion of the panel and their expert feedback, which was excellent on all counts. The consortium is excited to continue work on the objectives for RP2 which are well underway,  encompassing the recommendations of our scientific experts.

The MagnaPharm consortium would like to thank the external independent experts for taking part in this review and for their ongoing support of the MagnaPharm Project:

  

Professor Joop Ter Horst - Strathclyde Institute of Pharmacy and Biomedical Sciences

Professor Yaroslav Khimyak - University of East Anglia

 

Professor Richard Hill - University of Nottingham

Ms Man-Sze Li - Innovation Expert & Private Investor

Consortium members In attendance from each of the partner sites were:

University of Bristol:

Dr Simon Hall

Jason Potticary 

Nicole Dixon

University of Limerick:

Prof Ursel Bangert

Dr Andrew Stewart

Dr Jennifer Cookman

University College London:

Prof Sally Price FRS

Dr Rui Guo

Dr Louise Price

Radboud University:

Prof Dr Peter Christianen

Dr Sanne Granneman

Dr Hans Engelkamp

© 2017 MagnaPharm. All Rights Reserved

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

This project has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement number 736899.

Email: Nicole.dixon@bristol.ac.uk